Nothing Special   »   [go: up one dir, main page]

NO20005051L - Adjuvantsammensetninger - Google Patents

Adjuvantsammensetninger

Info

Publication number
NO20005051L
NO20005051L NO20005051A NO20005051A NO20005051L NO 20005051 L NO20005051 L NO 20005051L NO 20005051 A NO20005051 A NO 20005051A NO 20005051 A NO20005051 A NO 20005051A NO 20005051 L NO20005051 L NO 20005051L
Authority
NO
Norway
Prior art keywords
adjuvant
relates
present
vaccine
adjuvantsammensetninger
Prior art date
Application number
NO20005051A
Other languages
Norwegian (no)
Other versions
NO20005051D0 (en
Inventor
Martin Friede
Philippe Hermand
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9807805.8A external-priority patent/GB9807805D0/en
Priority claimed from GBGB9820956.2A external-priority patent/GB9820956D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of NO20005051D0 publication Critical patent/NO20005051D0/en
Publication of NO20005051L publication Critical patent/NO20005051L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse vedrører en addjuvantsammensetning som omfatter en poly-oksyetyleneter eller en polyoksyetylenester i kombinasjon med en farmasøytisk aksep-tabel eksipient og en vaksine som omfatter slike adjuvantsammensetninger og antigen. I tillegg vedrører foreliggende oppfinnelse anvendelse av polyoksygenetere eller -estere i fremstilling av adjuvantformuleringer og vaksineformuleringer og deres anvendelse som medikamenter.The present invention relates to an adjuvant composition comprising a polyoxyethylene ether or a polyoxyethylene ester in combination with a pharmaceutically acceptable excipient and a vaccine comprising such adjuvant compositions and antigen. In addition, the present invention relates to the use of polyoxygen ethers or esters in the manufacture of adjuvant and vaccine formulations and their use as medicaments.

NO20005051A 1998-04-09 2000-10-06 Adjuvantsammensetninger NO20005051L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9807805.8A GB9807805D0 (en) 1998-04-09 1998-04-09 Vaccine
GBGB9820956.2A GB9820956D0 (en) 1998-09-25 1998-09-25 Vaccine
PCT/EP1999/002278 WO1999052549A1 (en) 1998-04-09 1999-03-29 Adjuvant compositions

Publications (2)

Publication Number Publication Date
NO20005051D0 NO20005051D0 (en) 2000-10-06
NO20005051L true NO20005051L (en) 2000-11-21

Family

ID=26313462

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005051A NO20005051L (en) 1998-04-09 2000-10-06 Adjuvantsammensetninger

Country Status (15)

Country Link
EP (1) EP1069910A1 (en)
JP (1) JP2002511423A (en)
KR (1) KR20010042573A (en)
CN (1) CN1296416A (en)
AR (1) AR019026A1 (en)
AU (1) AU746163B2 (en)
BR (1) BR9909915A (en)
CA (1) CA2325939A1 (en)
HU (1) HUP0101619A3 (en)
IL (1) IL138000A0 (en)
NO (1) NO20005051L (en)
NZ (1) NZ506603A (en)
PL (1) PL354714A1 (en)
TR (1) TR200002930T2 (en)
WO (1) WO1999052549A1 (en)

Families Citing this family (229)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69737413T2 (en) 1996-01-04 2007-10-31 Novartis Vaccines and Diagnostics, Inc., Emeryville BACTERIOFERRITINE FROM HELICOBACTER PYLORI
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1077722B1 (en) 1998-05-22 2006-08-09 Ottawa Health Research Institute Methods and products for inducing mucosal immunity
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP1878424A3 (en) * 1999-09-24 2008-04-09 GlaxoSmithKline Biologicals S.A. Novel vaccine
BR0014285A (en) * 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvants comprising a polyoxyethylene alkyl ester or ether and at least one nonionic surfactant
EP1311288A1 (en) * 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
PL209127B1 (en) 2000-02-23 2011-07-29 Smithkline Beecham Biolog Tumour-specific animal proteins
DE60134134D1 (en) 2000-05-19 2008-07-03 Corixa Corp PROPHYLACTIC AND THERAPEUTIC TREATMENT OF TEN WITH COMPOUNDS BASED ON MONOSACCHARIDES
JP5139618B2 (en) 2000-06-20 2013-02-06 コリクサ コーポレイション Mycobacterium tuberculosis fusion protein
ATE396265T1 (en) 2000-06-28 2008-06-15 Corixa Corp COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER
IL155073A0 (en) * 2000-10-02 2003-10-31 Glaxosmithkline Biolog Sa Split enveloped virus preparation
AU1412702A (en) 2000-10-27 2002-05-06 Chiron Spa Nucleic acids and proteins from streptococcus groups a and b
JP2004535765A (en) 2000-12-07 2004-12-02 カイロン コーポレイション Endogenous retrovirus up-regulated in prostate cancer
CA2439111A1 (en) * 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
EP1988097A1 (en) 2001-05-09 2008-11-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
CZ20033515A3 (en) 2001-06-29 2005-01-12 Chiron Corporation HCV E1E2 vaccine composition
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
EP1581119B1 (en) 2001-12-17 2013-01-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
AU2003215316A1 (en) 2002-02-20 2003-09-09 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
SE0201701D0 (en) * 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
AU2003276679A1 (en) 2002-06-13 2003-12-31 Chiron Corporation Vectors for expression of hml-2 polypeptides
ATE394671T1 (en) * 2002-07-24 2008-05-15 Centre Nat Rech Scient METHOD FOR IDENTIFYING BIOLOGICALLY ACTIVE COMPOUNDS THAT HAVE ANTI-ASTHMATIC AND/OR ANTI-ALLERGIC PROPERTIES
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US20040132652A1 (en) * 2002-08-30 2004-07-08 Shire Biochem Inc. Pharmaceutical compositions
PT2353608T (en) 2002-10-11 2020-03-11 Novartis Vaccines And Diagnostics S R L Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
DK2241325T3 (en) 2002-10-29 2012-04-10 Coley Pharm Group Inc Use of CPG oligonucleotides to treat Hepatitis Cvirus infection
EP1562982B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
RU2544850C2 (en) 2003-01-06 2015-03-20 Корикса Корпорейшн Some amino alkyl glucose aminide phosphate derivatives and thereof application
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US10272147B2 (en) 2003-01-30 2019-04-30 Glaxosmithkline Biologicals S.A. Injectable vaccines against multiple meningococcal serogroups
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
CA2522379C (en) 2003-04-10 2012-10-23 Chiron Corporation The severe acute respiratory syndrome coronavirus
JP5557415B2 (en) 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Immunogenic compositions based on microparticles containing adsorbed toxoid and polysaccharide-containing antigens
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
PT1961426E (en) 2003-10-02 2011-06-28 Novartis Vaccines & Diagnostic Combined meningitis vaccines
ATE554106T1 (en) 2003-12-23 2012-05-15 Arbor Vita Corp ANTIBODIES FOR ONCOGENIC STRAINS OF HPV AND METHOD OF USE THEREOF
CA2559371C (en) 2004-03-09 2014-07-08 Chiron Corporation Influenza virus vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
PL1740217T3 (en) 2004-04-30 2012-03-30 Novartis Ag Meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
WO2006078294A2 (en) 2004-05-21 2006-07-27 Novartis Vaccines And Diagnostics Inc. Alphavirus vectors for respiratory pathogen vaccines
WO2006031264A2 (en) 2004-05-25 2006-03-23 Oregon Health And Science University Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
EP2277595A3 (en) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
EP2612679A1 (en) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
NZ555937A (en) 2005-01-27 2009-05-31 Childrens Hosp & Res Ct Oak GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
DK2351772T3 (en) 2005-02-18 2016-09-05 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis / sepsis-associated Escherichia coli
US8062644B2 (en) 2005-02-18 2011-11-22 Novartis Vaccines & Diagnostics Srl. Immunogens from uropathogenic Escherichia coli
CA2602637A1 (en) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
ZA200800146B (en) * 2005-08-03 2009-10-28 Immunogen Inc Immunoconjugate formulations
US20110223197A1 (en) 2005-10-18 2011-09-15 Novartis Vaccines And Diagnostics Inc. Mucosal and Systemic Immunization with Alphavirus Replicon Particles
EP1776963A1 (en) * 2005-10-19 2007-04-25 Gbf-Gesellschaft Für Biotechnologische Forschung Mbh Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
PL1945252T3 (en) 2005-11-04 2013-11-29 Seqirus Uk Ltd Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
JP5215865B2 (en) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
JP6087041B2 (en) 2006-01-27 2017-03-08 ノバルティス アーゲー Influenza virus vaccine containing hemagglutinin and matrix protein
EP2010537B1 (en) 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
JP2009534303A (en) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー Preserving influenza vaccines that are not refrigerated
SG173336A1 (en) 2006-03-31 2011-08-29 Novartis Ag Combined mucosal and parenteral immunization against hiv
ATE522541T1 (en) 2006-06-09 2011-09-15 Novartis Ag BACTERIAL ADHESIN CONFORMERS
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA2659552A1 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
EP1897557A1 (en) 2006-09-07 2008-03-12 Helmholtz-Zentrum für Infektionsforschung GmbH Use of glycolipids as adjuvants
CA2663196A1 (en) 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
EP2679240A1 (en) 2006-12-06 2014-01-01 Novartis AG Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
JP5378350B2 (en) 2007-04-04 2013-12-25 インフェクティアス ディジーズ リサーチ インスティチュート Immunogenic composition comprising Mycobacterium tuberculosis polypeptide and fusions thereof
CA2692200A1 (en) 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
MX2010001284A (en) 2007-08-02 2010-08-31 Biondvax Pharmaceuticals Ltd Multimeric multiepitope influenza vaccines.
JP2010535504A (en) 2007-08-03 2010-11-25 プレジデント アンド フェロウズ オブ ハーバード カレッジ Chlamydia antigen
MX2010002773A (en) 2007-09-12 2010-03-31 Novartis Ag Gas57 mutant antigens and gas57 antibodies.
EA026990B1 (en) 2007-11-07 2017-06-30 Селлдекс Терапьютикс Инк. Antibodies which bind to human cell dec-205
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2227250A4 (en) 2007-12-03 2011-07-06 Harvard College Chlamydia antigens
ES2664753T3 (en) 2007-12-07 2018-04-23 Glaxosmithkline Biologicals Sa Immune response induction compositions
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
RU2498994C2 (en) 2007-12-21 2013-11-20 Новартис Аг Mutant shapes of o-streptolysin
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
CA2717870A1 (en) 2008-03-10 2009-09-17 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
CN102239253A (en) 2008-12-03 2011-11-09 普罗蒂亚维仕尼科技有限公司 Glutamyl trna synthetase (GTS) fragments
PE20142330A1 (en) 2008-12-09 2015-01-14 Pfizer Vaccines Llc IGE CH3 PEPTIDE VACCINE
US8465751B2 (en) 2009-01-12 2013-06-18 Novartis Ag Cna—B domain antigens in vaccines against gram positive bacteria
RU2011140508A (en) 2009-03-06 2013-04-20 Новартис Аг Chlamydia antigens
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
EP2424562B1 (en) 2009-04-30 2015-10-07 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
EP2944320A1 (en) 2009-06-15 2015-11-18 National University of Singapore Influenza vaccine, composition, and methods of use
SG177533A1 (en) 2009-07-07 2012-02-28 Novartis Ag Conserved escherichia coli immunogens
TW201116294A (en) 2009-07-15 2011-05-16 Novartis Ag RSV F protein compositions and methods for making same
AU2010272243A1 (en) 2009-07-16 2012-03-08 Novartis Ag Detoxified Escherichia coli immunogens
CA2768346A1 (en) 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
EP2470204B1 (en) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
DK2473605T3 (en) 2009-09-03 2018-05-28 Pfizer Vaccines Llc PCSK9-VACCINE
BR112012009014B8 (en) 2009-09-30 2022-10-04 Novartis Ag PROCESS FOR PREPARING S. AUREUS CAPSULAR POLYSACCHARIDE CONJUGATE TYPE 5 OR TYPE 8 AND CRM197 TRANSPORT MOLECULE, CONJUGATE AND IMMUNOGENIC COMPOSITION
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
WO2011051893A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
EP2496609A4 (en) 2009-11-03 2013-05-08 Ligocyte Pharmaceuticals Inc Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
NZ629256A (en) 2009-12-22 2016-02-26 Celldex Therapeutics Inc Vaccine compositions
EP2519265B1 (en) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Polysaccharide immunogens conjugated to e. coli carrier proteins
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
ES2910199T3 (en) 2010-03-30 2022-05-11 Childrens Hospital & Res Center At Oakland Factor H-binding proteins (fHbp) with altered properties and methods of using them
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011127316A1 (en) 2010-04-07 2011-10-13 Novartis Ag Method for generating a parvovirus b19 virus-like particle
US9597326B2 (en) 2010-04-13 2017-03-21 Glaxosmithkline Biologicals Sa Benzonapthyridine compositions and uses thereof
BR112012026227A2 (en) 2010-04-13 2020-08-04 Celldex Therapeutics, Inc. human or humanized monoclonal antibody, bispecific molecule, expression vector, transformed cell, composition, and, uses of an antibody
KR20130121699A (en) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 Interactive hybrid asynchronous computer game infrastructure
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
EP2576613A1 (en) 2010-06-07 2013-04-10 Pfizer Inc. Her-2 peptides and vaccines
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
CN103154242B (en) 2010-07-06 2015-09-30 诺华股份有限公司 The immunogenic composition that norovirus is derivative and method
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US20130345079A1 (en) 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
ES2859673T3 (en) 2010-11-08 2021-10-04 Infectious Disease Res Inst Vaccines comprising nonspecific nucleoside hydrolase polypeptides and sterol 24-c-methyltransferase (SMT) for the treatment and diagnosis of leishmaniasis
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CN106822882A (en) * 2010-12-14 2017-06-13 葛兰素史密丝克莱恩生物有限公司 Mycobacterial antigen composition
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
SI2667892T1 (en) 2011-01-26 2019-05-31 Glaxosmithkline Biologicals Sa Rsv immunization regimen
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
SG194755A1 (en) 2011-05-13 2013-12-30 Novartis Ag Pre-fusion rsv f antigens
CN103608030A (en) 2011-06-21 2014-02-26 昂科发克特公司 Compositions and methods for therapy and diagnosis of cancer
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
WO2013006842A2 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
WO2013016460A1 (en) 2011-07-25 2013-01-31 Novartis Ag Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
US9511130B2 (en) 2011-09-14 2016-12-06 Glaxosmithkline Biologicals Sa Escherichia coli vaccine combination
AU2012349753A1 (en) 2011-12-08 2014-06-19 Novartis Ag Clostridium difficile toxin-based vaccine
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
MX2014010011A (en) 2012-02-24 2014-09-08 Novartis Ag Pilus proteins and compositions.
EP3492095A1 (en) 2012-04-01 2019-06-05 Technion Research & Development Foundation Limited Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
ES2837825T3 (en) 2012-04-26 2021-07-01 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2844282B1 (en) 2012-05-04 2019-06-12 Pfizer Inc Prostate-associated antigens and vaccine-based immunotherapy regimens
SG11201407440WA (en) 2012-05-22 2014-12-30 Novartis Ag Meningococcus serogroup x conjugate
EP2869842A1 (en) 2012-07-06 2015-05-13 Novartis AG Immunogenic compositions and uses thereof
RU2659149C2 (en) 2012-08-03 2018-06-28 Инфекшес Дизиз Рисерч Инститьют Compositions and methods for treating active mycobacterium tuberculosis infection
CN105307684A (en) 2012-10-02 2016-02-03 葛兰素史密丝克莱恩生物有限公司 Nonlinear saccharide conjugates
WO2014053612A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic composition
ES2826555T3 (en) 2012-11-30 2021-05-18 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combination
WO2014160987A2 (en) 2013-03-28 2014-10-02 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
WO2015132619A1 (en) 2013-05-15 2015-09-11 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
ES2820824T3 (en) 2014-01-21 2021-04-22 Pfizer Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
RU2714248C2 (en) 2014-07-23 2020-02-13 Чилдрен'З Хоспитал Энд Рисёрч Сентер Эт Окленд Versions of factor n-binding protein and methods of use thereof
AR102548A1 (en) 2014-11-07 2017-03-08 Takeda Vaccines Inc VACCINES AGAINST HAND, FEET AND MOUTH DISEASE AND MANUFACTURING AND USE METHODS
MA40920A (en) 2014-11-07 2017-09-12 Takeda Vaccines Inc VACCINES OF THE HAND, FOOT AND MOUTH, AND METHODS OF MANUFACTURING AND USE THEREOF
ES2881346T3 (en) 2014-12-19 2021-11-29 Regenesance B V Antibodies that bind to human C6 and uses thereof
HRP20230416T1 (en) 2015-01-15 2023-07-07 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
MX2017015004A (en) 2015-05-26 2018-07-06 Ohio State Innovation Foundation Nanoparticle based vaccine strategy against swine influenza virus.
CA2986494A1 (en) 2015-06-03 2016-12-08 Affiris Ag Il-23-p19 vaccines
AU2016289497A1 (en) 2015-07-07 2017-12-07 Affiris Ag Vaccines for the treatment and prevention of IgE mediated diseases
SG10202005253TA (en) 2015-07-21 2020-07-29 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3377098A1 (en) 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
EP3405212B1 (en) 2016-01-19 2020-07-08 Pfizer Inc Cancer vaccines
BR112018071307A2 (en) 2016-04-18 2019-02-26 Celldex Therapeutics, Inc. human cd40 binding agonist antibodies and uses thereof
EP3458088A2 (en) 2016-05-21 2019-03-27 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
MX2019003035A (en) 2016-09-16 2019-09-13 Infectious Disease Res Inst Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy.
HUE059252T2 (en) 2017-01-20 2022-11-28 Pfizer Immunogenic compositions for use in pneumococcal vaccines
US11123415B2 (en) 2017-08-16 2021-09-21 Ohio State Innovation Foundation Nanoparticle compositions for Salmonella vaccines
CN111511395B (en) 2017-11-03 2024-10-15 武田疫苗股份有限公司 Methods for inactivating Zika virus and for determining completeness of inactivation
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
CA3097369A1 (en) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
US20220118077A1 (en) 2018-09-11 2022-04-21 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
EP3893926A1 (en) 2018-12-12 2021-10-20 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7239509B6 (en) 2019-02-22 2023-03-28 ファイザー・インク Method for purifying bacterial polysaccharides
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
KR20220092572A (en) 2019-11-01 2022-07-01 화이자 인코포레이티드 Escherichia coli composition and method therefor
NL2030835B1 (en) 2020-01-24 2022-12-29 Aim Immunotech Inc Methods, compositions, and vaccinces for treating a virus infection
CA3171864A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
AU2021223184B2 (en) 2020-02-23 2024-10-10 Pfizer Inc. Escherichia coli compositions and methods thereof
CN115175924A (en) 2020-02-26 2022-10-11 港大科桥有限公司 PD-1 based vaccines against coronavirus infection
AU2021310952A1 (en) * 2020-07-24 2023-02-23 The Board Of Trustees Of The Leland Stanford Junior University A three component vaccine for COVID-19
KR20230096033A (en) 2020-10-27 2023-06-29 화이자 인코포레이티드 Escherichia coli composition and method thereof
MX2023005221A (en) 2020-11-04 2023-05-16 Pfizer Immunogenic compositions for use in pneumococcal vaccines.
WO2022101745A2 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
IL305313A (en) 2021-02-19 2023-10-01 Sanofi Pasteur Meningococcal b recombinant vaccine
IL307519A (en) 2021-04-09 2023-12-01 Celldex Therapeutics Inc Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
WO2022234483A1 (en) 2021-05-04 2022-11-10 King Abdullah University Of Science And Technology Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
WO2022249107A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112023023671A2 (en) 2021-05-28 2024-02-06 Pfizer IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACHARIDE ANTIGENS AND USES THEREOF
WO2023079528A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
WO2023079529A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Re-focusing protein booster immunization compositions and methods of use thereof
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
CN118434441A (en) 2021-11-18 2024-08-02 马特里瓦克斯公司 Immunogenic fusion protein compositions and methods of use thereof
KR20240128715A (en) 2022-01-13 2024-08-26 화이자 인코포레이티드 Immunogenic composition comprising conjugated membrane saccharide antigen and use thereof
KR102420201B1 (en) * 2022-01-17 2022-07-13 주식회사 유이케미칼 Eco-friendly quarantine composition with virus killing function with phospholipid envelope
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024018061A1 (en) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Use of bordetella strains for the treatment of chronic obstructive pulmonary disease
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024130009A1 (en) 2022-12-14 2024-06-20 Yale University Compositions and methods of use thereof for the treatment of virally driven cancers
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024186635A2 (en) 2023-03-03 2024-09-12 Celldex Therapeutics, Inc. Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
DE3867635D1 (en) * 1987-03-13 1992-02-20 Micro Vesicular Systems LIPID VERSICLE FROM INTERFACE-ACTIVE SUBSTANCES AND STEROLS.
JPH05201877A (en) * 1992-01-30 1993-08-10 Kanebo Ltd Adjuvant composition
GB9207731D0 (en) * 1992-04-07 1992-05-27 Proteus Molecular Design Improvements in or relating to vaccines
JPH06172216A (en) * 1992-12-04 1994-06-21 Norin Suisanshiyou Kachiku Eisei Shikenjo Emulsion-like oil adjuvant
DK17093D0 (en) * 1993-02-15 1993-02-15 Lyfjathroun H F PHARMACEUTICAL PREPARATION FOR TOPIC ADMINISTRATION OF ANTIGANTS AND / OR VACCINES FOR MAMMALS THROUGH MILES
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
ATE328890T1 (en) * 1994-07-15 2006-06-15 Univ Iowa Res Found IMMUNOMODULATORY OLIGONUCLEOTIDES

Also Published As

Publication number Publication date
CA2325939A1 (en) 1999-10-21
IL138000A0 (en) 2001-10-31
TR200002930T2 (en) 2000-12-21
NO20005051D0 (en) 2000-10-06
WO1999052549A1 (en) 1999-10-21
BR9909915A (en) 2000-12-26
JP2002511423A (en) 2002-04-16
AU3419799A (en) 1999-11-01
PL354714A1 (en) 2004-02-09
NZ506603A (en) 2002-10-25
AU746163B2 (en) 2002-04-18
HUP0101619A3 (en) 2003-11-28
CN1296416A (en) 2001-05-23
KR20010042573A (en) 2001-05-25
EP1069910A1 (en) 2001-01-24
HUP0101619A2 (en) 2001-08-28
AR019026A1 (en) 2001-12-26

Similar Documents

Publication Publication Date Title
NO20005051L (en) Adjuvantsammensetninger
EA200801307A1 (en) VACCINE COMPOSITIONS CONTAINING SAPONIN ADJUVANT
MY129263A (en) Vaccine composition
CO5680456A2 (en) COMPOSITIONS OF VACCINES THAT INCLUDE LIPOOLIGOSACARIDS OF IMMUNOTIPE L2 AND / OR L3 FROM LGTB-NEISSERIA MINIGITIDIS
DK1187629T3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2002028422A3 (en) Split enveloped virus preparation for intranasal delivery
HUP0203817A2 (en) Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
DE60020570D1 (en) ROTAVIRUS VACCINE FORMULATIONS
WO2002009746A8 (en) Vaccines comprising outer membrane vesciles from gram negative bacteria
SE0202110D0 (en) Iscom preparation and use thereof
NO20052010L (en) Immunogenic composition
EP2275122A3 (en) Protein-based streptococcus pneumoniae vaccines
CL2009001682A1 (en) Spontaneously dispersible pharmaceutical composition for oral administration comprising n-benzoyl-staurosporine; method to increase levels of bioavailability. (divisional of only 333-00).
HUP0401606A2 (en) West nile vaccine
AU2002221519A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
DE69940406D1 (en) INE RSV SUB-COMPOSITION COMPOSITION AND INFLUENZAVIRUS PREPARATION CONTAINS
PT792165E (en) IMMUNOGENIC COMPOSITIONS
HK1138516A1 (en) Parenteral vaccine formulations and uses thereof
WO2001070265A3 (en) Lipopeptide adjuvants
EP1905449A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
ECSP034579A (en) COMBINATION OF ADJUSTMENT FORMULATIONS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application